Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04439227 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Results posted: Oct 6, 2026 Eligibility criteria shortened, about 17 words · Secondary endpoints revised (2) · Primary endpoint revised · 1 more Show 4 more changesShow less
    • Eligibility criteria shortened, about 17 words
    • Secondary endpoints revised (2)
    • Primary endpoint revised
    • Study description expanded, about 17 words
  2. Start date: Mar 13, 2017 to Mar 24, 2017 Secondary endpoints revised (2)v31 Show 1 more changeShow less
    • Secondary endpoints revised (2)

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion moved earlier from Dec 31, 2026 to May 29, 2020 Enrollment target: estimated 35 to confirmed 33v30 Show 1 more changeShow less
    • Enrollment target: estimated 35 to confirmed 33
  4. 2 versions Re-verified since Oct 30, 2025, no change to tracked fieldsv28-v29
  5. Primary and study completion dates: Dec 31, 2025 to Dec 31, 2026v27
Show 25 earlier versionsHide 25 earlier versions
  1. Re-verified, no change to tracked fieldsv26
  2. Primary and study completion dates: Jun 30, 2025 to Dec 31, 2025v25
  3. 3 versions Re-verified since May 3, 2024, no change to tracked fieldsv22-v24
  4. Primary and study completion dates: Jun 30, 2024 to Jun 30, 2025v21
  5. Re-verified, no change to tracked fieldsv20
  6. Primary and study completion dates: Jun 30, 2023 to Jun 30, 2024v19
  7. 4 versions Re-verified since Jun 28, 2022, no change to tracked fieldsv15-v18
  8. Primary and study completion dates: May 31, 2022 to Jun 30, 2023v14
  9. 3 versions Re-verified since Jul 2, 2021, no change to tracked fieldsv11-v13
  10. Primary completion date: Apr 30, 2021 to May 31, 2022 Completion date: Aug 9, 2021 to May 31, 2022v10 Show 1 more changeShow less
    • Completion date: Aug 9, 2021 to May 31, 2022
  11. Re-verified, no change to tracked fieldsv9
  12. Primary completion date: Jan 31, 2021 to Apr 30, 2021v8
  13. Re-verified, no change to tracked fieldsv7
  14. Primary completion date: Oct 31, 2020 to Jan 31, 2021v6
  15. 2 versions Re-verified since Oct 14, 2020, no change to tracked fieldsv4-v5
  16. Primary completion date: Mar 4, 2019 to Oct 31, 2020 Enrollment target: 33 to 35 · Completion date: Aug 9, 2020 to Aug 9, 2021v3 Show 2 more changesShow less
    • Enrollment target: 33 to 35
    • Completion date: Aug 9, 2020 to Aug 9, 2021
  17. Enrollment target: 35 to 33v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II MATCH treatment trial identifiesay block the protein tyrosine kinase WEE1 the effects of AZD1775 in patients whose cancer has a genetic change called BRCA mutation. AZD1775 may block a protein called WEE1, which may be needed for growth of cancer cells that express BRCA mutations. Researchers hope to learn if AZD1775 will shrink this type of cancer or stop its growth.
Trial Details
NCT Number NCT04439227
Lead Sponsor National Cancer Institute (NCI)
Conditions Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Enrollment 33 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov